This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Previously-solved crystal structure indicates that AFABP exists in the dimeric state in solution when no ligands are present. The configuration of the dimer is expected to change upon binding of the drug troglitazone or the endogenous ligand 15d-PGJ2. AFABP action is implicated in metabolic syndrome and the onset of diabetes in humans. We believe that changes in the oligomeric state should be visible in SAXS envelopes.
Showing the most recent 10 out of 375 publications